Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 12/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.52 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188534 | 0.90 | PIK3CG (0.78) | PIK3CGMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL189004 | 0.89 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL14050556 | 0.89 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189522 | 0.89 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188486 | 0.89 | PIK3CG (0.73) | PIK3CGMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL189527 | 0.89 | PIK3CG (0.73) | PIK3CGMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL189014 | 0.89 | PIK3CG (0.76) | PIK3CGMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL188330 | 0.87 | PIK3CG (0.71) | PIK3CGMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL188455 | 0.86 | PIK3CG (0.70) | PIK3CGMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3578934 | 0.86 | PIK3CG (1.00) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885MAPT 4580/4885PIK3CD 2/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885MAPT 4580/4885PIK3CD 2/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 6/4885MAPT 4606/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.